Mallinckrodt PLC Company Profile (NYSE:MNK)

About Mallinckrodt PLC

Mallinckrodt PLC logoMallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: MNK
  • CUSIP:
Key Metrics:
  • Previous Close: $53.38
  • 50 Day Moving Average: $50.12
  • 200 Day Moving Average: $61.30
  • 52-Week Range: $42.67 - $85.83
  • Trailing P/E Ratio: 20.71
  • Foreward P/E Ratio: 6.42
  • P/E Growth: 1.12
  • Market Cap: $5.59B
  • Outstanding Shares: 104,694,000
  • Beta: 1.48
Profitability:
  • Net Margins: 7.75%
  • Return on Equity: 17.34%
  • Return on Assets: 5.71%
Debt:
  • Debt-to-Equity Ratio: 1.18%
  • Current Ratio: 1.20%
  • Quick Ratio: 0.93%
Additional Links:
Companies Related to Mallinckrodt PLC:

Analyst Ratings

Consensus Ratings for Mallinckrodt PLC (NYSE:MNK) (?)
Ratings Breakdown: 2 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $82.91 (51.85% upside)

Analysts' Ratings History for Mallinckrodt PLC (NYSE:MNK)
Show:
DateFirmActionRatingPrice TargetDetails
2/21/2017Canaccord GenuityInitiated CoverageBuy -> Buy$91.00View Rating Details
2/8/2017Leerink SwannSet Price TargetBuy$60.00View Rating Details
2/8/2017Piper Jaffray CompaniesLower Price TargetOverweight$108.00 -> $83.00View Rating Details
2/3/2017MizuhoLower Price TargetBuy$85.00 -> $69.00View Rating Details
1/25/2017J P Morgan Chase & CoSet Price TargetHold$78.00View Rating Details
1/19/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$72.00View Rating Details
1/19/2017Wells Fargo & CoReiterated RatingBuyView Rating Details
1/19/2017GuggenheimSet Price TargetBuy$98.00View Rating Details
11/30/2016Deutsche Bank AGLower Price TargetBuy$78.00 -> $73.00View Rating Details
11/29/2016BMO Capital MarketsReiterated RatingOutperform$92.00View Rating Details
11/18/2016Raymond James Financial, Inc.Initiated CoverageOutperform$72.00View Rating Details
9/21/2016Morgan StanleyReiterated RatingBuy$82.00View Rating Details
8/26/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$83.00View Rating Details
8/25/2016Barclays PLCReiterated RatingOverweight$88.00View Rating Details
8/12/2016Stifel NicolausInitiated CoverageBuy$95.00View Rating Details
8/4/2016Jefferies Group LLCReiterated RatingBuy$85.00 -> $95.00View Rating Details
3/16/2016Northland SecuritiesReiterated RatingBuy$95.00View Rating Details
2/2/2016NomuraReiterated RatingNeutral$100.00View Rating Details
10/7/2015Bank of America CorpLower Price TargetBuy$135.00 -> $131.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Mallinckrodt PLC (NYSE:MNK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2017        
2/7/2017Q117$1.82$1.91$827.12 million$829.90 millionViewListenView Earnings Details
11/29/2016Q416$2.01$2.04$880.10 million$887.20 millionViewListenView Earnings Details
8/2/2016Q316$2.00$2.20$920.35 million$970.60 millionViewListenView Earnings Details
5/3/2016Q216$1.72$2.01$878.70 million$918.00 millionViewListenView Earnings Details
2/2/2016Q116$1.77$2.00$888.33 million$915.00 millionViewListenView Earnings Details
11/23/2015Q415$1.77$1.84$869.41 million$882.40 millionViewListenView Earnings Details
8/4/2015Q315$1.82$2.05$983.81 million$965.10 millionViewListenView Earnings Details
5/5/2015Q215$1.48$1.72$860.89 million$909.90 millionViewListenView Earnings Details
2/3/2015Q115$1.55$1.84$880.12 million$866.00 millionViewListenView Earnings Details
11/19/2014Q414$1.41$1.68$759.04 million$789.00 millionViewListenView Earnings Details
8/7/2014Q314$0.87$1.20$278.80 million$653.10 millionViewListenView Earnings Details
5/8/2014Q214$0.78$0.95$566.50 million$557.80 millionViewListenView Earnings Details
2/6/2014Q1$0.66$0.88$539.24 million$540.20 millionViewListenView Earnings Details
11/7/2013$0.85$1.02$572.57 million$552.20 millionViewListenView Earnings Details
8/9/2013Q3 2013$0.78$0.49$557.22 million$570.00 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mallinckrodt PLC (NYSE:MNK)
Current Year EPS Consensus Estimate: $7.56 EPS
Next Year EPS Consensus Estimate: $8.51 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 201610$1.64$1.87$1.77
Q2 20169$1.95$2.09$2.05
Q3 20163$1.98$2.14$2.04
Q4 20163$1.88$2.19$1.99
Q1 20173$1.60$1.77$1.70
Q2 20173$1.90$1.95$1.93
Q3 20173$1.85$1.91$1.88
Q4 20173$2.02$2.07$2.05
Q1 20183$1.82$2.15$2.01
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Mallinckrodt PLC (NYSE:MNK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mallinckrodt PLC (NYSE:MNK)
Insider Ownership Percentage: 0.53%
Institutional Ownership Percentage: 88.79%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/23/2017Meredith B. FischerinsiderBuy2,000$54.34$108,680.00View SEC Filing  
2/14/2017Mark TrudeauInsiderBuy1,000$50.47$50,470.00View SEC Filing  
2/10/2017Steven J. RomanoVPBuy1,000$49.68$49,680.00View SEC Filing  
5/10/2016Hugh M O'neillVPBuy1,653$60.99$100,816.47View SEC Filing  
5/10/2016Matthew K HarbaughCFOBuy500$59.37$29,685.00View SEC Filing  
5/6/2016Mark TrudeauCEOBuy1,000$56.02$56,020.00View SEC Filing  
5/6/2016Steven J RomanoVPBuy900$56.00$50,400.00View SEC Filing  
3/4/2016Coleman N Lannum IIIVPBuy2,600$62.63$162,838.00View SEC Filing  
2/26/2016Meredith B FischerVPBuy1,400$69.80$97,720.00View SEC Filing  
2/12/2016Coleman N Lannum IIIVPBuy600$59.66$35,796.00View SEC Filing  
2/10/2016Coleman N Lannum IIIVPBuy1,300$62.58$81,354.00View SEC Filing  
2/9/2016Matthew K. HarbaughCFOBuy1,300$63.00$81,900.00View SEC Filing  
2/8/2016Coleman N. Lannum IIIVPBuy800$66.37$53,096.00View SEC Filing  
12/22/2015Coleman N Lannum IIISVPBuy500$72.50$36,250.00View SEC Filing  
12/11/2015Terrance L CarlsonGeneral CounselBuy1,000$69.10$69,100.00View SEC Filing  
12/2/2015Gary M. PhillipsVPBuy1,000$72.17$72,170.00View SEC Filing  
11/30/2015Mark TrudeauCEOBuy1,350$65.89$88,951.50View SEC Filing  
11/27/2015Coleman N Lannum IIISVPBuy1,200$66.86$80,232.00View SEC Filing  
11/27/2015Meredith B FischerVPBuy2,200$66.93$147,246.00View SEC Filing  
11/27/2015Terrance L CarlsonGeneral CounselBuy1,000$66.54$66,540.00View SEC Filing  
8/25/2015Hugh M O'neillSVPBuy1,197$83.52$99,973.44View SEC Filing  
8/25/2015Mark TrudeauCEOBuy1,000$83.08$83,080.00View SEC Filing  
8/21/2015Coleman N Lannum IIISVPBuy2,375$88.52$210,235.00View SEC Filing  
8/21/2015Mark TrudeauCEOBuy2,000$88.45$176,900.00View SEC Filing  
6/4/2015Coleman N Lannum IIIVPBuy1,300$126.41$164,333.00View SEC Filing  
6/2/2015Matthew K HarbaughCFOSell22,106$128.64$2,843,715.84View SEC Filing  
5/18/2015Mario D SaltarelliVPSell4,580$127.44$583,675.20View SEC Filing  
5/13/2015Don M BaileyDirectorSell51,417$122.45$6,296,011.65View SEC Filing  
5/11/2015Sandra L HattenVPSell2,024$122.29$247,514.96View SEC Filing  
4/13/2015Don M BaileyDirectorSell40,000$127.61$5,104,400.00View SEC Filing  
3/13/2015Don M BaileyDirectorSell40,000$123.40$4,936,000.00View SEC Filing  
2/13/2015Don M BaileyDirectorSell33,891$114.63$3,884,925.33View SEC Filing  
2/2/2015Mark TrudeauCEOSell11,925$105.94$1,263,334.50View SEC Filing  
1/9/2015Mark TrudeauCEOSell15,720$102.00$1,603,440.00View SEC Filing  
12/22/2014Peter G EdwardsVPSell1,265$99.69$126,107.85View SEC Filing  
12/18/2014Mark TrudeauCEOSell13,831$93.59$1,294,443.29View SEC Filing  
9/10/2014Raymond J FureyVPSell5,441$85.90$467,381.90View SEC Filing  
9/8/2014Don M BaileyDirectorSell221,177$85.23$18,850,915.71View SEC Filing  
9/5/2014Raymond J FureyVPSell15,000$85.47$1,282,050.00View SEC Filing  
9/5/2014Virgil D ThompsonDirectorSell25,000$83.76$2,094,000.00View SEC Filing  
9/2/2014Raymond J FureyVPSell10,303$81.61$840,827.83View SEC Filing  
8/29/2014Raymond J FureyVPSell4,840$80.90$391,556.00View SEC Filing  
8/19/2014Joseph A ZaccagninoDirectorBuy3,000$71.06$213,180.00View SEC Filing  
8/13/2014Paulson & Co IncMajor ShareholderBuy132,100$69.80$9,220,580.00View SEC Filing  
8/12/2014J Martin CarrollDirectorBuy2,000$69.24$138,480.00View SEC Filing  
8/12/2014Paulson & Co IncMajor ShareholderBuy467,900$68.78$32,182,162.00View SEC Filing  
8/11/2014Paulson & Co IncMajor ShareholderBuy207,900$69.70$14,490,630.00View SEC Filing  
8/7/2014Paulson & Co IncMajor ShareholderBuy700,200$70.15$49,119,030.00View SEC Filing  
8/1/2014Paulson & Co IncMajor ShareholderBuy275,000$69.60$19,140,000.00View SEC Filing  
6/11/2014Melvin D BoothDirectorBuy4,000$76.05$304,200.00View SEC Filing  
5/9/2014Paulson & Co Incmajor shareholderBuy786,207$73.63$57,888,421.41View SEC Filing  
2/3/2014Mark TrudeauCEOSell14,890$56.12$835,626.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Mallinckrodt PLC (NYSE:MNK)
DateHeadline
News IconMallinckrodt plc (NYSE:MNK) Stock Price Target Given At $78.307 - Transcript Daily (NYSE:MNK)
transcriptdaily.com - February 26 at 7:01 AM
News IconStock ABR Of Mallinckrodt plc (NYSE:MNK) At 1.25 | Stock Observer - Stock Observer (NYSE:MNK)
www.thestockobserver.com - February 26 at 7:01 AM
finance.yahoo.com logoDEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Mallinckrodt Public Limited Company To Contact The Firm (NYSE:MNK)
finance.yahoo.com - February 26 at 7:01 AM
News IconFocusing the Lens on Mallinckrodt plc (NYSE:MNK) Earnings & Projections - Winfield Review (NYSE:MNK)
winfieldreview.com - February 25 at 12:49 AM
News IconAre Analysts Optimistic About Where Mallinckrodt plc (NYSE:MNK) is Heading? - Winfield Review (NYSE:MNK)
winfieldreview.com - February 25 at 12:49 AM
finance.yahoo.com logoMALLINCKRODT SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Mallinckrodt Public Limited Company – (NYSE:MNK)
finance.yahoo.com - February 25 at 12:49 AM
4-traders.com logoMallinckrodt : To Present At Barclays Global Healthcare Conference (NYSE:MNK)
www.4-traders.com - February 24 at 7:49 PM
finance.yahoo.com logoMallinckrodt To Present At Barclays Global Healthcare Conference (NYSE:MNK)
finance.yahoo.com - February 24 at 7:49 PM
News IconMallinckrodt indicated as Buy By Canaccord Genuity (NYSE:MNK)
prensariotiretail.com - February 23 at 11:40 PM
globenewswire.com logoMNK INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of ... (NYSE:MNK)
globenewswire.com - February 23 at 11:40 PM
4-traders.com logoMALLINCKRODT PLC : Change in Directors or Principal Officers (form 8-K) (NYSE:MNK)
www.4-traders.com - February 23 at 11:40 PM
News IconPrice Target Review on Mallinckrodt plc (NYSE:MNK) - Rockville Register (NYSE:MNK)
rockvilleregister.com - February 23 at 6:40 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Mallinckrodt Public Limited Company (MNK) and Lead Plaintiff Deadline - March 27, 2017 (NYSE:MNK)
finance.yahoo.com - February 23 at 6:40 PM
biz.yahoo.com logoMALLINCKRODT PLC Files SEC form 8-K, Change in Directors or Principal Officers (NYSE:MNK)
biz.yahoo.com - February 23 at 6:40 PM
globenewswire.com logoMNK INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action ... - GlobeNewswire (press release) (NYSE:MNK)
www.globenewswire.com - February 23 at 8:00 AM
seekingalpha.com logoMallinckrodt: Risk From Both The Massachusetts AG And The DOJ Remain - Seeking Alpha (NYSE:MNK)
seekingalpha.com - February 23 at 8:00 AM
News IconMNK INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action ... - EconoTimes (NYSE:MNK)
www.econotimes.com - February 22 at 6:44 PM
News IconMallinckrodt PLC (MNK) is Initiated by Canaccord Genuity to “Buy” - Highland Mirror (NYSE:MNK)
www.highlandmirror.com - February 22 at 6:44 PM
seekingalpha.com logoMallinckrodt: Why Synacthen Could Threaten Acthar - Seeking Alpha (NYSE:MNK)
seekingalpha.com - February 22 at 6:44 PM
finance.yahoo.com logoCoverage initiated on Mallinckrodt plc by Canaccord Genuity (NYSE:MNK)
finance.yahoo.com - February 22 at 6:44 PM
finance.yahoo.com logoMNK INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Mallinckrodt plc and a Lead Plaintiff Deadline of March 27, 2017 (NYSE:MNK)
finance.yahoo.com - February 22 at 6:44 PM
openpr.com logoMallinckrodt PLC (NYSE:MNK) Investor Lawsuit alleges False and Misleading Statements (NYSE:MNK)
www.openpr.com - February 20 at 5:56 PM
News IconImpact of Brokerage Rating on Mallinckrodt PLC(MNK) - Highland Mirror (NYSE:MNK)
www.highlandmirror.com - February 17 at 3:34 PM
finance.yahoo.com logoBlog Coverage The Biologics License Application for Mylan-Biocon's Proposed Biosimilar - Pegfilgrastim, Gets Accepted by US FDA for Review (NYSE:MNK)
finance.yahoo.com - February 17 at 3:34 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint to Recover Losses Suffered by Investors in Mallinckrodt plc (NYSE:MNK)
finance.yahoo.com - February 17 at 3:34 PM
News IconPresident and CEO of Mallinckrodt plc Ordinary Share (NYSE:MNK), Trudeau Mark, buys 1,000 shares worth $50,466 (NYSE:MNK)
empowerednews.net - February 16 at 6:10 PM
News IconThe Brokers Set Expectations for Mallinckrodt PLC's FY2021 Earnings (MNK) (NYSE:MNK)
www.graffiotech.com - February 16 at 6:10 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Mallinckrodt Public Limited Company (MNK) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit (NYSE:MNK)
us.rd.yahoo.com - February 16 at 6:10 PM
us.rd.yahoo.com logoMallinckrodt plc -- Moody's assigns Ba1 to Mallinckrodt's new senior secured term loan (NYSE:MNK)
us.rd.yahoo.com - February 16 at 6:10 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Mallinckrodt Public Limited Company (MNK) & Lead Plaintiff Deadline -- March 27, 2017 (NYSE:MNK)
us.rd.yahoo.com - February 16 at 6:10 PM
realistinvestor.com logoDeferred Tax Assets Of Mallinckrodt plc (NYSE:MNK) At $115.7 Millions - RealistInvestor.com (NYSE:MNK)
www.realistinvestor.com - February 14 at 8:09 PM
businesswire.com logoMNK INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Mallinckrodt plc - Business Wire (press release) (NYSE:MNK)
www.businesswire.com - February 14 at 8:09 PM
finance.yahoo.com logoMNK INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Mallinckrodt plc (NYSE:MNK)
finance.yahoo.com - February 14 at 8:09 PM
News IconMallinckrodt plc (NYSE:MNK) Projected to Achieve EPS Of $1.64 - Stock Observer (NYSE:MNK)
www.thestockobserver.com - February 13 at 7:43 PM
bizjournals.com logoMedicare spent $650M on 1 drug of questionable use: OHSU study (NYSE:MNK)
www.bizjournals.com - February 13 at 7:43 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Investors in Mallinckrodt plc Lead Plaintiff Deadline of March 27, 2017 (NYSE:MNK)
finance.yahoo.com - February 13 at 7:43 PM
News IconLarge Outflow of Money Witnessed in Mallinckrodt plc - Highland Mirror (NYSE:MNK)
www.highlandmirror.com - February 13 at 10:15 AM
News IconStock ABR Of Mallinckrodt plc (NYSE:MNK) At 1.27 - Stock Observer (NYSE:MNK)
www.thestockobserver.com - February 12 at 4:45 AM
finance.yahoo.com logoMALLINCKRODT PLC Financials (NYSE:MNK)
finance.yahoo.com - February 11 at 6:42 PM
finance.yahoo.com logoMALLINCKRODT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Mallinckrodt Public Limited Company - (NYSE:MNK)
finance.yahoo.com - February 11 at 12:30 AM
News IconResearch Analysts Set Expectations for Mallinckrodt PLC's Q1 2017 Earnings (MNK) (NYSE:MNK)
hoyentv.com - February 10 at 7:28 PM
us.rd.yahoo.com logoLESS THAN TWO MONTHS REMAIN FOR MALLINCKRODT INVESTORS: Hagens Berman Reminds Mallinckrodt Investors of March 27, 2017 Lead Plaintiff Deadline (NYSE:MNK)
us.rd.yahoo.com - February 10 at 7:28 PM
News IconMallinckrodt Plc MNK Medical Equipment Deals and Alliances Profile Prices from USD $250 (NYSE:MNK)
www.bioportfolio.com - February 9 at 7:37 PM
News IconMallinckrodt PLC (MNK) Releases FY Earnings Guidance (NYSE:MNK)
xboxonezone.com - February 9 at 7:37 PM
News IconWhat Analysts Report Shows About Mallinckrodt plc (NYSE:MNK)? - Transcript Daily (NYSE:MNK)
transcriptdaily.com - February 9 at 5:28 AM
us.rd.yahoo.com logoEdited Transcript of MNK earnings conference call or presentation 7-Feb-17 1:30pm GMT (NYSE:MNK)
us.rd.yahoo.com - February 8 at 7:26 PM
capitalcube.com logoMallinckrodt Plc :MNK-US: Earnings Analysis: Q1, 2017 By the Numbers : February 8, 2017 (NYSE:MNK)
www.capitalcube.com - February 8 at 7:26 PM
bizjournals.com logoMallinckrodt receives subpoenas (NYSE:MNK)
www.bizjournals.com - February 8 at 7:26 PM
finance.yahoo.com logoMNK LOSS NOTICE: Rosen Law Firm Reminds Mallinckrodt Public Limited Company Investors of Important Deadline in Class Action (NYSE:MNK)
finance.yahoo.com - February 8 at 7:26 PM
investors.com logoTop-selling drug helps Mallinckrodt to strong finish in 2016 (NYSE:MNK)
www.proactiveinvestors.com - February 7 at 7:55 PM

Social

What is Mallinckrodt PLC's stock symbol?

Mallinckrodt PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

Where is Mallinckrodt PLC's stock going? Where will Mallinckrodt PLC's stock price be in 2017?

17 brokers have issued 1 year price objectives for Mallinckrodt PLC's shares. Their predictions range from $60.00 to $98.00. On average, they anticipate Mallinckrodt PLC's stock price to reach $82.91 in the next year.

When will Mallinckrodt PLC announce their earnings?

Mallinckrodt PLC is scheduled to release their next quarterly earnings announcement on Tuesday, February, 7th 2017.

What are analysts saying about Mallinckrodt PLC stock?

Here are some recent quotes from research analysts about Mallinckrodt PLC stock:

  • According to Zacks Investment Research, "Mallinckrodt reported strong results for the transition quarter (Oct 1 to Dec 30) beating both sales and earnings expectations. The results were driven by volume-based growth across its Specialty Brands segment which once more offset the ongoing challenges in Specialty Generics segment. Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures. The company sold its Nuclear Imaging business due to lingering challenging conditions for quite some time. The company also announced to sell its Intrathecal Therapy business. Meanwhile, Mallinckrodt acquire-to-invest policy is apparently paying off as both Inomax and Therakos continue to witness solid demand along with Ofirmev. The performance of Acthar has been impressive too. Estimates for 2017 have gone up post the strong results. However, shares have underperformed the Medical-Generic Drugs industry in 2017." (2/9/2017)

  • Guggenheim analysts commented, "Although any potential competition for MNK's largest single drug, Acthar, is a concern, we think that it will take at least several years for Marathon to even establish proof of concept for its product, which means there is no near-to-mid-term threat here. We forecast Acthar sales of $1.2B in '16 and total MNK sales of $3.3B. We believe that MNK's execution of its stated business objectives is underappreciated and would note that the company has a demonstrated record of success, supported by consistent earnings beats over the last five quarters. We continue to believe strong execution of MNK's growth initiatives will drive P/E multiple expansion (from 6x to at least 10x, average pharma trough multiple) and put MNK shares back on a path to $70+." (1/19/2017)
  • Mizuho analysts commented, "Yesterday MNK sold off based on headlines of an FTC anti-trust investigation, then rebounded quickly after a $100M settlement was announced. This settlement was related to legacy Synacthen issues associated with its Questcor acquisition. The stock then plunged again on more detailed news that Mallinckrodt would need to license two Synacthen indications (infantile spasms and nephrotic syndrome) to an undisclosed company. Investors were concerned that this could introduce additional competition to Acthar and create yet another overhang on the stock. Management held a call this morning that, in our view, dispelled most if not all of these concerns as outlined below. We reiterate our Buy rating on the stock and expect a rebound." (1/19/2017)

Who owns Mallinckrodt PLC stock?

Mallinckrodt PLC's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Paulson & CO. Inc. (7.62%), State Street Corp (4.67%), AQR Capital Management LLC (3.09%), Janus Capital Management LLC (2.75%), Orbimed Advisors LLC (1.41%) and Dimensional Fund Advisors LP (1.36%). Company insiders that own Mallinckrodt PLC stock include Coleman N Lannum III, Don M Bailey, Gary M Phillips, Hugh M O'neill, Mario D Saltarelli, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Sandra L Hatten, Steven J Romano and Terrance L Carlson.

Who sold Mallinckrodt PLC stock? Who is selling Mallinckrodt PLC stock?

Mallinckrodt PLC's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Janus Capital Management LLC, Asset Management One Co. Ltd., Oxford Asset Management, Barings LLC, United Capital Financial Advisers LLC, Loomis Sayles & Co. L P and Prudential PLC.

Who bought Mallinckrodt PLC stock? Who is buying Mallinckrodt PLC stock?

Mallinckrodt PLC's stock was bought by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., AQR Capital Management LLC, Guggenheim Capital LLC, Deerfield Management Co., Senzar Asset Management LLC, Orbimed Advisors LLC, State Street Corp and Allianz Asset Management AG. Company insiders that have bought Mallinckrodt PLC stock in the last two years include Coleman N Lannum III, Gary M Phillips, Hugh M O'neill, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Steven J Romano and Terrance L Carlson.

How do I buy Mallinckrodt PLC stock?

Shares of Mallinckrodt PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Mallinckrodt PLC stock cost?

One share of Mallinckrodt PLC stock can currently be purchased for approximately $54.60.

Mallinckrodt PLC (NYSE:MNK) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Mallinckrodt PLC (NYSE:MNK)

Earnings History Chart

Earnings by Quarter for Mallinckrodt PLC (NYSE:MNK)

Dividend History Chart

Dividend Payments by Quarter for Mallinckrodt PLC (NYSE:MNK)

Last Updated on 2/27/2017 by MarketBeat.com Staff